Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EyePoint Pharmaceuticals Inc.

http://eyepointpharma.com

Latest From EyePoint Pharmaceuticals Inc.

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

What Does 2019 Hold For Biopharma?

Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.

C-Suite Speaks Business Strategies

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Asia Deal Watch: Innovent Picks Up Asian Rights To Three Clinical Cancer Candidates From Incyte

Incyte gets $40m up front and can earn up to $351.5m in milestones pegged to a Phase III JAK1 inhibitor and a pair of Phase II candidates. Shionogi obtains Asian rights to an allosteric inhibitor for cognitive disorders from Tetra.

Asia Pacific Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Cancer
  • Ophthalmic
  • Alias(es)
  • pSivida Ltd.
  • pSivida Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • EyePoint Pharmaceuticals Inc.
  • Senior Management
  • Nancy Lurker, Pres. & CEO
    David Price, CFO
    Thomas Hadley, VP, Mktg. & Sales
    Dario Paggiarino, MD, SVP, CMO
    Scott Jones, Chief Commercial Officer
    Said Saim, PhD, CTO
    Marty Nazzaro , SVP, Operations
  • Contact Info
  • EyePoint Pharmaceuticals Inc.
    Phone: (833) 393-7646
    400 Pleasant St., Ste. B300
    Watertown, 02472
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register